# Michael Dickinson

Source: https://onco.cc/people/michael-dickinson/  
OnCo record `michael-dickinson` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma.

## Summary

Michael Dickinson was principal investigator and first author of the pivotal phase 2 trial of glofitamab, the CD20xCD3 bispecific antibody that produces durable complete remissions in about 40% of patients with relapsed or refractory large B-cell lymphoma after two or more lines, including after CAR-T, leading to its approval. He leads bispecific and CAR-T trials at Peter Mac and the Australasian Leukaemia and Lymphoma Group aggressive lymphoma programme.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; bispecific; australia
- Role: Lead, Aggressive Lymphoma Program, Peter MacCallum Cancer Centre and Royal Melbourne Hospital
- Specialisms: Aggressive lymphoma; Bispecific antibodies; CAR T-cell therapy; Early drug development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Dickinson%20MJ%5BAuthor%5D%20glofitamab

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD20](https://onco.cc/targets/cd20/), [CD3](https://onco.cc/targets/cd3/)
- drugs: [Glofitamab](https://onco.cc/drugs/glofitamab/)
- institutions: [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- trials: [STARGLO](https://onco.cc/trials/starglo/)
- key papers: [Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma](https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/michael-dickinson.json